When can the practicing physician suspect white coat hypertension? Statement from the Working Group on Blood Pressure Monitoring of the European Society of Hypertension.

Open Access
Publisher Website
Google Scholar
Abstract
The Centers for Medicare and Medicaid Services (CMS) in the United States have recently approved ambulatory blood pressure measurement (ABPM) for reimbursement, but only for “patients with suspected WCH (white coat hypertension)” in whom the CMS believes the information deriving from the technique “is necessary in order to determine the appropriate management of the patient.”1 This decision, which is likely to change the clinical management of hypertension in the United States, makes white coat hypertension a condition of major importance. The decision by the CMS begs the question as to how the practicing physician can select patients with white coat hypertension. It might indeed be argued that all patients with an elevated clinic blood pressure (BP) are candidates for ABPM. However, the CMS decision carries a few other stipulations. First, white coat hypertension should be defined as “office BP >140/90 mm Hg on at least three separate clinic/office visits with two separate measurements made at each visit.” Second, in addition “there should be at least two BP measurements taken outside the office which are 1

This publication has 0 references indexed in Scilit: